CDSCO extends shelf life of Bharat Biotech’s Covaxin up to 12 months

"This approval of shelf life extension is based on the availability of additional stability data, which was submitted to CDSCO," Bharat Biotech said.

By: Express Web Desk
New Delhi | Updated: November 3, 2021 05:27 PM IST

1 min read

Covaxin, UK approved travel list, Covid-19, Covishield, UK, World news, Indian express, Indian express news, current affairs

A health worker prepares to administer the Covaxin Covid-19 vaccine. (Express photo by Partha Paul)

Hyderabad-based vaccine manufacturer Bharat Biotech on Wednesday announced that the Central Drugs Standard Control Organisation (CDSCO) has approved the shelf life extension of Covaxin Covid-19 vaccine to 12 months from the date of manufacture.

This came just hours before the World Health Organisation (WHO) recommended the Emergency Use Listing status for Bharat Biotech’s Covaxin on Wednesday, according to PTI.

In a tweet, the company stated, “This approval of shelf life extension is based on the availability of additional stability data, which was submitted to CDSCO. The shelf life extension has been communicated to our stakeholders.”

Earlier, Australia’s regulator, the Therapeutic Goods Administration (TGA), had said that Covaxin would be “recognised for the purpose of establishing a traveller’s vaccination status”. Apart from Australia, several countries like Greece, Oman, Mauritius and Philippines, among others had approved Covaxin for travel much before WHO’s approval.

From the homepage